Ion channel modulators that enhance acetylcholine release: Potential therapies for Alzheimer’s disease

Expert Opinion on Investigational Drugs

Volumn 7, Issue 4, 1998, Pages 499-518

  Chorvat, Robert j ^a   Zaczek, Robert ^a   Brown, Barry s ^a  

^a DUPONT COMPANY   (United States)

Author keywords

ACh release enhancement; Alzheimer s disease; BDZ GABAA receptor ligands; calcium channel activators; ligand gated ion channel; M current; nicotinic cholinergic agonists; potassium channel blockers; voltage gated ion channel

Indexed keywords

EID: 0000694559     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.7.4.499     Document Type: Review

References (140)

1. BONDI MW, SALMON DP, BUTTERS NM: Neuropsycho-logical features of memory disorders. In: Alzheimer's Disease. Terry RD, Katzman R, Bick KL (Eds.), Raven Press, New York, USA (1993): 41 – 64.
2. SELKOE DJ: Normal and abnormal biology of the I3-am-yloid precursor protein. Ann. Rev. Neurosci. Cowan WM (Ed.) (1994): 489 – 518.
3. YANKNER BA: Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 16 (5): 921 – 932.
4. GOEDERT M: Tau protein and the neuroflbrillary pa-thology of Alzheimer's disease. Trends Neurosci. (1993) 16 (10460 – 465.
5. MCGEER PL, MCGEER EG: Immune mechanisms in neu-rodegenerative disorders. Drugs Today (1996) 32: 149 – 158.
6. COCHRAN FR, VITEK MP: Neuroinflammatory mecha-nisms in Alzheimer's disease: opportunities of drug discoveries. Exp. Opin. Invest. Drugs (1996) 5: 449 – 455.
7. ROGERS J, COOPER NR, WEBSTER S et al.: Complement activation by I3-amyloid in Alzheimer's disease. Proc. Natl Acad. ScL USA (1992) 89: 10016 – 10020.
8. PALMER AM: Neurochemical studies of Alzheimer's dis- ease. Neurodegeneration (1996) 5: 381 – 391.
9. BARTUS RT, DEAN RL, III., BEER B, LIPPA AS: The cho-linergic hypothesis of geriatric memory dysfunction. Science (1982) 217: 408 – 417.
10. MASH DC, FLYNN DD, POTTER LT: Loss of M2 muscar-inic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science (1985) 228: 1115 – 1157.
11. SUGAYA K, GIACOBINI E, CHIAPPINELLI VA: Nicotinicacetylcholine receptor subtytpes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. (1990) 27: 349 – 359.
12. WHITEHOUSE PJ, KELLAR KJ: Nicotinic and muscariniccholinergic receptors in Alzheimer's disease and re-lated disorders. J. Neural Transm. Suppl. (1987) 24: 175 – 182.
13. PEARCE B, POTTER LT: Coupling of M1 muscarinic re-ceptors to G-proteins in Alzheimer's disease. Alz. Dis. Assoc. Disord. (1991) 5: 163 – 172.
14. DEFEUDIS FV: Central cholinergic systems, cholinergic drugs and Alzheimer's disease - an overview. Drugs To-day (1988) 24 (7): 473 – 490.
15. IVERSON LL: The cholinergic hypothesis of dementia. Trends Pharm. Sci. (1986) (Suppl.): 44 – 45.
16. PERRY EK, TOMLINSON BE, BLESSED G et al: Correlationof cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. (1978) 2: 1457 – 1459.
17. PERRY EK: The cholinergic hypothesis - ten years on. Br. Med. Bull. (1986) 42 (1): 63 – 69.
18. COYLE JT, PRICE DL, DELONG MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 219: 1184 – 1190.
19. WHITEHOUSE PJ, PRICE DL, STRUBLE RG et al.: Alz-heimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 215: 1237 – 1239.
20. IYO M, NAMBA H, FUKUSHI H et al: Measurement of ace-tycholinesterase by positron emission tomography in the brains of healthy controls and patients with Alz-heimer's disease. Lancet (1997) 349: 1805 – 1809.
21. NORDBERG A: Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res. (1993) 57: 215 – 224.
22. KUHL DE, MINOSHIMA S, FESSLER JA et al: In vivo map-ping of cholinergic terminals in normal aging, Alz-heimer's disease, and Parkinson's disease. Ann. Neurol (1996) 40 (3): 399 – 410.
23. EL-DEFRAWY SR, COLOMA F, JHAMANDAS K et al Func- tional and neurochemical cortical cholinergic impair-ment following neurotoxic lesions of the nucleus basalis magnocellularis in the rat. Neurobiol. Aging (1985) 6: 325 – 330.
24. HEPLER DJ, WENK GL, CRIBBS BL, OLTON DS, COYLE JT: Memory impairments following basal forebrain le-sions. Brain Res. (1985) 346: 8 – 14.
25. WATSON M, VICKROY TW, FIBIGER HC, ROESKE WR, YA-MAMURA HI: Effects of bilateral ibotenate-induced le-sions of the nucleus basalis magnocellularis upon selective cholinergic biochemical markers in the rat anterior cerebral cortex. Brain Res. (1985) 346: 387 – 391.
26. BARTUS RT: Evidence for a direct cholinergic involve-ment in the scopolamine induced amnesia in mon-keys: effects of concurrent administration of physostigmine and methylphenidate with scopola-mine. Pharmacol. Biochem. Behav. (1978) 9(6) 833 – 836.
27. CAULFIELD MP, FORTUNE DH, ROBERTS PM, STUBLEY JK: Intracerebroventricular hemicholinium-3 (HC-3) impairs learning of a passive avoidance task in mice. Br. J. Pharmacol (1981) 74: 865.
28. KNAPP MJ, KNOPMAN DS, SOLOMON PR etal: A 30-weekrandomized controlled trial of high dose tacrine in pa-tients with Alzheimer's disease. JAMA (1994) 271: 985 – 991.
29. ROGERS SL, DOODY R, MOHS R, FRIEDHOFF LT: E2020 produces both clinical global and cognitive test im-provement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week Phase III trial. Neurology (1996) 46 (Suppl.): A217.
30. ROGERS S: Clinical profile of donepezil (E2020). 5th In-ternational Conference on Alzheimer's Disease and Related Disorders. (1996) 181.
31. NORDBERG A, LILJA A, HARTVIG P et al.: Tacrine re-stores cholinergic nicotinic and glucose metabolism in Alzheimer patients as visualized by positron emis-sion tomography. Neurobiol. Aging (1992) 13: 747 – 758.
32. CHORVAT RJ, EARL RA, ZACZEK R: Acetylcholine release enhancing agents: potential therapeutics for Alz-heimer's disease. Drugs Fut. (1995) 20: 1145 – 1162.
33. ADAM-VIZI V, LIGETI E: Release of acetylcholine from rat brain synaptosomes by various agents in the ab-sence of external calcium ions. J. Physiol. (fond.) (1984) 353: 505 – 521.
34. CATTERALL WA: Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Ann. Rev. Pharmacol. Toxicol. (1980) 20: 15 – 43.
35. NICKOLSON VJ, TAM SW, MYERS MJ, COOK L: DUP 996(3,3-bis (4-pyrindinylmethy0-1-phenylindolin-2-one enhances the stimulus-induced release of acetylcho-line from rat brain in vitro and in vivo. Drug Dev. Res. (1990) 19: 285 – 300.
36. ROBINSON TE, JUSTICE JB: Microdialysis in the Neuro-sciences. Robinson TE, Justice JJB (Ed.), Elsevier, Cam-bridge, UK (1991).
37. VAN DYCK CH, LIN CH, ROBINSON R et al: The acetyl-choline releaser linopirdine increases parietal regional blood flow in Alzheimer's disease. Psycho-pharmacology (1997) 132: 217 – 226.
38. GRAY EG: Axo-somatic and axo-dexdritic synapses ofthe cerebral cortex: an electron microscope study. J. Anat. (1959) 93: 420 – 433.
39. TRIFARO J-M, VITALE ML: Cytoskeleton dynamics dur- ing neurotransmitter release. Trends Neurosci. (1993) 16 (10466 – 472.
40. EDWARDS RH: The transport of neurotransmitters into synaptic vesicles. Curr. Opin. Neurobiol (1992) 2: 586 – 594.
41. WAHL LM, POUZAT C, STRATFORD KJ: Monte Carlo simulation of fast excitatory synaptic transmission at at a hippocampal synapse. J. Neurophysiol. (1996) 75 (2): 597 – 608.
42. CLEMENS JD: Transmitter timecourse in the synaptic cleft: its role in central synaptic function. Trends Neuro-sci. (1996) 19 (5): 163 – 171.
43. THOMAS P, WONG JG, LEE AK: A low affinity Ca ++ recep-tor controls the final steps in peptide secretion from pituitary melanotrophs. Neuron (1993) 11: 93 – 104.
44. BAJJALIEH SM SCHELLER RH: The biochemistry of neu-rotransmitter secretion. J. Biol. Chem. (1995) 270: 1971 – 1974
45. BURGOYNE RD, MORGAN A: Regulated exocytosis. Bio-chem J. (1993) 293: 305 – 316.
46. AUGUSTINE GJ, ADLER EM, CHARLTON MP: The calcium signal for transmitter secretion from presynaptic nerve terminals. Ann. NY Acad. Sci. (1991) 635: 365 – 381.
47. LEVEQUE C, HOSHINO T, DAVID P: The synaptic vesicle protein synaptotagmin associates with calcium chan-nels and is a putative Lambert-Eaton myasthenic syn-drome antigen. Proc. NatL Acad. Sci. USA (1992) 89: 3625 – 3629.
48. SHOJI-KASAI Y, YOSHIDA A, SATO K et al.: Neurotrans-mitter release from synaptotagmin-deficient clonal variants of PC12 cells. Science (1992) 256: 1820 - 1823.
49. POPOV SV: Synaptogamin: a calcium sensitive inhibi-tor of exocytosis. Cell (1993) 73: 1247 – 1249.
50. BENNETT MR: Models and mechanisms of neurotrans-mission. In: Neurotransmitter Release and Its Modulation. Powis DA, Bunn SJ (Eds.), Cambridge University Press, Cambridge, UK (1995): 38 – 54.
51. KATZ B, MILEDI R: Estimates of the quantal content dur-ing 'chemical potentiation' of transmitter release. Proc. Royal. Soc. London, Series B (1979) 205: 369 – 378.
52. SIEGHART W: Multiplicity of GABAA-benzodiazepine receptors. Trends Pharm. Sci. (1989) 10: 407 – 411.
53. BORMANN J: Electrophysiology of GABAA and GABAB receptor sybtypes. Trends Neurosci. (1988) 11:112-116. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
54. SIEGHART W: GABAA receptors: ligand-gated cr ion channels modulated by multiple drug-binding sites. Trends Pharm. Sci. (1992) 13: 446 – 450.
55. SCATTON B, BARTHOLINI G: Modulation by GABA of cholinergic transmission in the striatum. Brain Res. (1980) 183: 211 – 216.
56. SCATTON B, BARTHOLINI G: Gamma-aminobutyric acid (GABA) receptor stimulation. IV. Effect of proga-bide (SL 76002) and other GABAergic agents on acetyl-choline turnover in rat brain areas. J. Pharmacol Exp. Ther. (1982) 220: 689 – 695.
57. STOOF JC, DENBREEJEN EJS, MULDER AH: GABA modu-lates the release of dopamine and acetylcholine from rat caudate nucleus slices. Eur. J. Pharmacol (1979) 57: 35 – 42.
58. SUPAVILAI P, KAROBATH M: Modulation of acetylcho-line release from rat striatal slices by the GABA/benzo-diazepine receptor complex. Life Sci. (1985) 36: 417 – 426.
59. ANDERSON JJ, KUO S, CHASE TN, ENGBER TM: GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo. NeuroscI Letts. (1993) 160: 126 – 130.
60. VENAULT P, CHAPOUTHIER G, PRADO DE CARVALHO L et al Benzodiazepine impairs and I3-carboline en-hances performance in learning and memory tasks. Nature (1986) 321 – 864.
61. ROY-BYRNE PP, UHDE TW, HOLCOMB H et al.: Effects of diazepam on cognitive processes in normal subjects. Psychopharmacology (Ben) (1987) 91: 30.
62. HAVOUNDJIAN H, REED GF, PAUL SM, SKOLNICK P: Pro-tection against the lethal effects of pentobarbital in mice by a benzodiazepine receptor inverse agonist, 6,7-dimethoxy-4-ethyl-3-carbmethoxy-b-carboline. J. Clin. Invest. (1987) 79: 473 – 477.
63. BRAESTRUP C, SCHMIECHEN R, NEEF G, NIELSEN M, PE-TERSEN EN: Interaction of convulsive ligands with ben-zodiazepine receptors. Science (1982) 216: 1241 – 1243.
64. SARTER M, BRUNO JP: Cognition enhancement medi-ated via transsynaptic, behavior-dependent stimula-tion of cortical acetylcholine release. Neuropsychopharmacology (1994) 10(3S/Part 1): S65 – 282.
65. MOORE H, SARTER M, BRUNO JP: Bidirectional modula-tion of stimulated cortical acetylcholine release by benzodiazepine receptor ligands. Brain Res. (1993) 627: 267 – 274.
66. MOORE H, SARTER M, BRUNO J: Age-dependent modula-tion of in vivo cortical acetylcholine release by benzo-diazepine receptor ligands. Brain Res. (1992) 596: 17 – 29.
67. DUKA T, GOERKE D, FICHTE K: Effects of ZK 93426, a beta-carboline benzodiazepine receptor antagonist on night sleep patterns in healthy male volunteers. Psy-chopharmacology (Berl.) (1995) 117 (2): 178 – 185.
68. SMITH CG, BENINGER RJ, RICHARD J et al.: Basal fore-brain injections of the benzodiazephine partial in-verse agonist FG 7142 enhance memory of rats in the double Y-maze. Brain Res. (1994) 655 (1): 61 – 67.
69. IMPERATO A, DAZZI L, OBINU MC, GESSA LG, BIGGIO G: The benzodiazepine receptor antagonist flumazenil increases acetylcholine release in rat hippocampus. Brain Res. (1994) 647: 167 – 171.
70. OTT BR, THOMPSON JA, WHELIHAN WM: Cognitive ef-fects of flumazenil in patients with Alzheimer's dis-ease. J. Clin. Psychopharmacol (1996) 16(5) 400 – 402.
71. KAWASAKI K, MASAMI E, MASATO I et al.: A novel benzo-diazepine inverse agonist, S-8510, as a cognitive en-hancer. Prog. Neuro-Psychopharmacol. Biol. Psychiat. (1996) 20: 1413 – 1425.
72. TAKADA S, SASATANI T, CHOMEI N et al: Synthesis and structure-activirty relationships of fused imidazopyri-dines: a new series of benzodiazepine receptor ligands. J Med. Chem. (1996) 39: 2844 – 2851.
73. HAMMOND C: The nicotinic acetylcholine receptor. In: Cellular and Molecular Neurobiology. Hammond C (Ed.), Academic Press, San Diego, CA, USA (1996): 214 – 247.
74. ROLE LW, BERG DK: Nicotinic receptors in the develop-ment and modulation of CNS synapses. Neuron (1996) 16: 1077 – 1085.
75. WILKIE GI, HUTSON P, SULLIVAN JP, WONNACOTT S: Pharmacological characterization of a nicotinic auto-receptor in rat hippocampal synaptosomes. Neuro-chem. Res. (1996) 21 (9): 1141 – 1148.
76. ARNERIC SP, HOLLADAY MW, SULLIVAN JP: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease. Exp. Opin. Invest. Drugs (1996) 5: 79 – 100
77. COURT JA, PERRY EK: CNS nicotinic receptors: possible therapeutic targets in neurodegenerative disorders. CNS Drugs (1994) 2: 216 – 233.
78. FLORES CM, ROGERS SW, PABREZA LA, WOLFE BB, KEL-LAR KJ: A subtype of nicotinic cholinergic receptor in rat brain is composed of a4 and 132 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharm. (1992) 41: 31 – 37.
79. CLARKE PBS, PERT A: Autoradiographic localization of putative nicotinic receptors in the rat brain using [125I]-neuronal bungarotoxin. Brain Res. (1985) 348: 355 – 358.
80. SHIGUELA P, WADICHE J, DINELEY-MILLER K, DANI JA, PATRICK JW: Molecular cloning, functional properties, and distribution of rat brain a7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. (1993) 13: 596 – 604.
81. MARTIN EJ, PANICKER KS, KING MA etal: Cytoprotective actions of 2,4-dimethylbenzylidene anabasine in dif-ferentiated PC12 cells and septal cholinergic neurons. Drug Dev. Res. (1994) 13: 131 – 141.
82. ARNERIC SP, SULLIVAN JP, BRIGGS CA et al.:(5)-3-methy1-5-(1methyl-2-pyrrolidinyl)isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: 1. In vitro charac-terization. J. Pharmacol. Exp.Ther. (1994) 270:310-318. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
83. DECKER MW, BRIONI JD, SULLIVAN JP et al.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidiinyl)isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and amdolytic activities: ii. in vivo charac-terization. J. Pharmacol. Exp. Ther. (1994) 270 (1) 319 – 328.
84. DAMAJ MI, CREASY KR, WELCH SP et al.: Comparative pharmacology of nicotine and ABT-418, a new nico-tinic agonist. Psychopharmacology (Berl.) (1995) 120(4) 483 – 490.
85. PENDERGRAST MA, TERRY AV, Jr., JACKSON WJ et al: Im-provement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic re-ceptor agonist ABT-418. Psychopharmacology (Berl.) (1997) 130 (3): 276 – 284.
86. BRIGGS CA, ANDERSON DJ, BRIONI JD et al.: Functional characterization of the novel neuronal nicotinic ace-tylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. (1997) 57 (1-2): 231 – 241.
87. SUMMERS KL, KEM WR, GIACOBINI E: Nicotinic agonist modulation of neurotransmitter levels in the rat fron-toparietal cortex. Jpn.J. Pharmacol (1997) 74(2) 139 – 146.
88. KATZ B MILEDI R: The timing of calcium action during neuromuscular transmission. J. Physiol. (1967) 189: 535 – 544.
89. WRAY W, NORMAN RI, HESS P: Calcium channels: struc-ture and function. Ann. NY Acad. Sci. (1989) 560: 1 – 475.
90. LLINAS R, SUGIMORI M, SILVER RB: Presynaptic calcium concentration microdomains and transmitter release. Physiol. (1992) 86 (1-3): 135 – 138.
91. KANDEL ER, SCHWARZ JH, JESSELL TM: Transmitter re-lease. In: Principles of Neural Science. Elsevier Science, New York, USA (1990: 194 – 212.
92. DUNLAP K, LUEBKE JI, TURNER TJ: Exocytotic Ca2+ chan-nels in mammalian central neurons. Trends Neurosci. (1995) 18: 89 – 98
93. SCHINDLER U, RUSH DK, FIELDING S: Nootropic drugs: animal models for studying effects on cognition. Drug Dev. Res. (1984) 4 (5): 567 – 76.
94. GOULIAEV AH, SENNING A: Piracetam and other struc-turally related nootropics. Brain Res. Rev. (1994) 19: 180 – 222.
95. NABESHIMA T, NAKAYAMA S, ICHIHARA K et al.: Effects of nefiracetam on drug-induced impairment of latent learning mice in a water finding task. Eur. J. Pharmacol (1994) 255: 57 – 65.
96. SAKURAI T, OJIMA H, YAMASAKI T, KOJIMA H, AKASHI A: Effects of N-(2,6-dimethylpheny1)-2-(2-oxo-1 - pyrrolidinyfiacetamide (DM-9384) on learning and memory in rats. Jpn. J. Pharmacol (1989) 50 (1): 47 – 53.
97. NAKAYAMA S, ICHIHARA K, YAMADA K et al: Effects ofnefiracetam on impairment of attention in latent learning task in mice. Neuropsychopharmaology (1994) 10: 58 – 89.
98. KAWAJIRI S, TANIGUCKI K, SAKURAI T, KOJIMA H, YA-MASAKI T: Effect of DM-9384 on extracellular acetyl-choline in the rat frontal cortex measured with microdialysis. Eur. j Pharmacol (1990) 183 (3): 928.
99. KAWAJIRI S, TANIGUCKI K, SAKURAI T, YAMASAKI T: Ne-firacetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat. J. Neural. Trans. (1994) 98: 15 – 22.
100. KROGSGAARD-LARSEN P, LUND M, JOERGENSEN S, BREHM L: Excitatory amino acid receptors: multiplicity and structural requirements for activation and block-ade. In: Excitatory Amino Acids and Synaptic Transmission. Wheal HV, Thomson AM (Eds.), Academic Press, London, UK (1990: 1 – 17.
101. YOSHII M, WATABE S: Enhancement of neuronal cal-cium channel currents by the nootropic agent, nefi-racetam (DM-9384), in NG108-15 cells. Brain Res. (1994) 642: 123 – 131.
102. STANLEY EF: Single calcium channels and acetylcho-line release at a presynaptic nerve terminal. Neuron (1993) 11: 1007 – 1011.
103. GOA KL, BENFIELD P: Nefiracetam (new drug profile). CNS Drugs (1996) 6 (4): 331 – 337.
104. NABESHIMA T: Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction. Shinkei Seishin Yakuri (1994) 16 (5): 309 – 333.
105. HALLIWELL JV: It channels in the central nervous sys-tem. In: Potassium Channels - Structure, Classification, Function and Therapeutic Potential. Cook NS (Ed.), Ellis Horwood Limited, Chichester, UK (1990): 348 – 381.
106. STJARNE L: Basic mechanism and local modulation of nerve impulse-induced secretion of neurotransmit-ters from individual sympathetic nerve varicosities. Rev. Physiol. Biochem. Pharmacol (1989) 112: 1 – 138.
107. STJARNE L, STJARNE E, MSGHINA M, BAO JX: It and Ca2+ channel blockers may enhance or depress sympa-thetic tramsmitter release via a Ca +-dependent mechanism 'upstream' of the release site. Neuroscience (1991) 44: 673 – 692.
108. SAINT DA, QUASTEL DM, GUAN YY: Multiple potassium conductances at the mammalian motor nerve termi-nal. Pflugers Arch. (1987) 410 (4-5): 408 – 412.
109. MACIAG CM, LOGUE AR, TINKER WJ et al.: Studies on the role of KF, a- and Na+ ion permeabilities in the acetyl-choline release enhancing effects of linopirdine (DuP 996) in rat cerebral cortical slices. J. Pharmacol Exp. Then. (1994) 271: 891 – 7.
110. WEISSLING H, AGOSTON S, VAN DAM GBP et al.: Effects of 4-aminopyridine in elderly patients with Alz-heimer's disease. New Eng. J. Med. (1984) 310: 988 – 989.
111. COOK NS: The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol. Sci. (1988) 9: 21 – 28.
112. KIM YI, GOLDNER MM, SANDERS DB: Facilitatory effects of 4-aminopyridine on normal neuromuscular trans-mission. Muscle Nerve (1980) 3:105-111. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
113. JANKOWSKA E, LUNDBERG A, RUDOMIN P, SYKOVA E: Effects of 4-aminopyridine on transmission in excita-tory and inhibitory synapses in the spinal cord. Brain Res. (1977) 136: 387 – 392.
114. MITSUHIKO M, RIKER WK: Effects of several aminopyri-dines and analogs on the calcium dependence of syn-aptic transmission. J. Pharmacol. Exp. Ther. (1984) 228: 573 – 578.
115. THOMAS AJ, KESTER JA, BUTLER DE et al.: Acetylcholine releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas. Bioorg. Med. Chem. Lett. (1992) 2 (8): 855 – 860.
116. ZACZEK R, CHORVAT RJ, EARL RA, TAM SW: Neurotrans-mitter release enhancement as a possible therapy for neurodegenerative diseases: update on linopirdine (DUP996). In: Alzheimer's Disease: Therapeutic Ap-proaches. Giacobini E, Becker RE (Eds.), Birkhauser, Bos-ton, MA, USA (1990 252 – 255.
117. MCEVOY KM, WINDEBANK AJ, DAUBE JR, LOW PA: 3,4,-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New Eng. J. Med. (1989) 23 (23): 1567 – 1571.
118. SUZUKI T, NONAKA H, FUJIMOTO K, KAWASHIMA K: Tacrine increases stimulation-evoked acetylcholine release from rat hippocampal slices. Jpn. J. Pharmacol. (1994) 65: 337 – 342.
119. KOJIMA J, SUGAWARA Y, OBARA S: NIK-247 blocks voltage-dependent ionic currents in crayfish axon. Jpn Pharmacol. (1991) 57 (545 – 552).
120. ISHII Y, SUMI T: Evaluation of a cholinergic drug, 9-amino-2,3,5,6,7,8-hexahydro-1 H-cyclopenta-(b)-qu-inoline (NIK-247), as an enhancer of endogenous ef-flux of acetylcholine from brain slices. Neuropharmacology (1992) 31: 61 – 66.
121. ISHII Y, KOJIMA J, IKEDA N, KAWASHIMA K: Effect of NIK-247 on basal concentrations of extracellular ace-tycholine in the cerebral cortex of conscious, freely moving rats. Jpn. J. Pharmacol. (1994) 66: 289 – 293.
122. ZACZEK R, CHORVAT RJ, BROWN BS: Linopirdine: phar-macology of a neurotransmitter release enhancer. CNS Drug Rev. (1997) 3 (2): 103 – 119.
123. VICKROY TW: Presynaptic cholinergic actions by the putative cognitive enhancing agent DuP 996. J. Phar-macol. Exp. Ther. (1993) 264 (2): 910 – 917.
124. TINKER WJ, MACIAG C, TAM SW, ZACZEK R: Effects of li-nopirdine (DuP 996) on KC1 and CaC12 dose response of potassium evoked release of NI acetylcholine from superfused hippocampal slices. Soc. Neurosci. Abstr. (1992) 18: 518 – 512.
125. LAMPE BW, BROWN BS: Electrophysiological effects of DuP 996 on hippocampal CA1 neurons. Soc. Neurosci. Abstr. (1991) 17: 1588.
126. AIKEN SP, LAMPE BJ, MURPHY PA, BROWN BS: Reduc-tion of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br. J. Pharmacol. (1995) 115: 1163 – 1168.
127. LAMPE BJ, GASKILL JL, KEIM SC, BROWN BS: Linopirdine reduces stimulus intensity threshold for induction of long-term potentiation in the Schaffer collateral/CA1 pathway in rat hippocampal slices. Neurosci. Letts. (1997) 222: 135 – 137.
128. COOK L, NICKOLSON VJ, STEINFELS GF, ROHRBACH KW, DENOBLE VJ: Cognition enhancement by the acetyl-choline releaser DuP 996. Drug Dev. Res. (1990) 19: 301 – 314.
129. ZACZEK R, SAYDOFF J: Depolarization activated releas-ers of transmitters as therapeutics for dementia: pre-clinical characterization of linopirdine (DuP 996). Curr. Opin. Invest. Drugs (1993) 2 (10): 1097 – 1104.
130. STORM JF: Potassium currents in hippocampal pyrami-dal cells. In: Progress in Brain Research. Storm-Mathisen J, Zimmer J, Ottersen OP (Eds.), Elsevier, Amsterdam (1990 161 – 187.
131. BROWN DA, ADAMS PR: Muscarinic suppression of a novel voltage-sensitive It current in a vertebrate neu-rone. Nature (1980) 283: 673 – 676.
132. BROWN DA: M-currents: an update. Trends Neurosci. (1988) 11: 294 – 299.
133. AIKEN SP, ZACZEK R, BROWN BS: Pharmacology of the neurotransmitter release enhancer linopirdine (DuP996), and insights into its mechanism of action. Adv. Pharmacol. (1996) 35: 349 – 384
134. LAMAS JA, SELYANKO AA, BROWN DA: Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (Imm)) and some other voltage-and ligand-gates membrane currents in rat sympa-thetic neurons. Eur. j Neurosci. (1997) 9: 605 – 616.
135. PIENIASZEK HJ, JR., FISKE WD, SAXTON TD et al.: Single-dose pharmacokinetics, safety, and tolerance of lino-pirdine (DuP 996) in healthy young adults and elderly volunteers. J. Clin. Pharmacol. (1995) 35 (1): 22 – 30.
136. SALETU B, DARRAGH A, BREUEL HP et al.: EEG mapping cntral effects of multiple doses of linopirdine - a cogni-tive enhancer - in healthy elderly male subjects. Hu-man PsychopharmacoL (1991) 6: 267 – 275.
137. RAKESTRAW DC, BILSKI DA, LAM GN: Determination of linopirdine and its N-oxide metabolites in rat plasma by liquid chromatography. J. Pharm. Biomed. Anal. (1994) 12 (8): 1055 – 1061.
138. EARL RA, MYERS MJ, JOHNSON AL et al.: Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures. Bioorg. Med. Chem. Lett. (1992) 2 (0851 – 854.
139. PIENIASZEK HJ, Jr., GARNER DM, KLINGERMAN CA, KORNHAUSER DM: Pharmacokinetics, safety and toler-ance of DMP-543, a potential cognitive enhancer, in © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4) young and elderly male subjects after single oral doses. J. OM. Pharmacol. (1997) 37 (9): 867.
140. E.P., LAVRETSKY, L.F., JARVIK, A group of potassium-channel blockers - acetylcholine releasers: new poten-tials for Alzheimer's disease?, JOM. Psychopharm., (1992), 12, 2, 110-118